Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A phase 2 randomised controlled trial will be performed in which the efficacy and safety of standard treatment (primary chemoradiation; consisting of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for six weeks) and experimental treatment (NACT; consisting of carboplatin and paclitaxel in a 3-weekly scheme) will be compared in 98 patients with LAVC, registered from eight national medical centres.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Primary chemoradiation | Active Comparator | Patients included in the standard treatment arm will receive a combination of weekly cisplatin combined with 30 fractions of external beam radiotherapy on the primary tumour with a total dose of 64.5 Gy. Cisplatin will be given for six weeks intravenously with a dose of 40 mg/m2, if possible on the first day of the week. On day 1 until day 5 the patient will receive external beam radiotherapy. This will be repeated for a six-week period. |
|
| NACT (3-weekly carboplatin and paclitaxel) followed by surgery | Experimental | Patients included in the experimental arm will be treated with intravenous infusion of paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme with preferably 3 and a maximum of 4 courses, with evaluation after two courses of chemotherapy by physical examination. NACT will be subsequently followed by radical surgery in responding patients. A four to six weeks interval after the last course of chemotherapy needs to be respected before surgery, to allow sufficient physical recovery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Paclitaxel and Carboplatin | Drug | Paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Loco-regional control after 24 months per completed treatment including salvage treatment | Proportion of patients free from local-regional progression | 24 months after completed treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Disease-related treatment failure | Patients without an event will be censored at their last date of contact. The Kaplan-Meier method will be used to estimate freedom from disease-related failure. Difference between the two main treatment arms, NACT vs. chemotherapy, will be tested using a log-rank test. Incidences of disease-related failure will be reported based on the Kaplan-Meier estimates, together with confidence intervals for the hazard ratio using both 90 and 95% confidence levels. |
Not provided
Inclusion Criteria:
Woman ≥ 18 years
Signed and written informed consent.
Histologically-confirmed primary or recurrent squamous cell carcinoma vulvar cancer FIGO stage Ib - IVa, T1b or higher, any N, M0.
Local tumour through which the size or localization implies requirement of treatment through primary chemoradiation or surgery consisting of extensive surgery (meaning surgery damaging pelvic organs or exenterative surgery). This can imply;
World Health Organization performance status of 0-2
Adequate haematological function defined by platelet count >100x10E9/L, absolute leukocyte >3X10E9/L or neutrophil count (ANC) >1.5x10E9/L, and hemoglobin >6.0 mmol/L
Adequate hepatic function defined by a total bilirubin level ≤1.5x the upper limit of normal (ULN) range and ASAT and ALAT levels ≤2.5x ULN for all subjects
Adequate renal function defined by an estimated creatinine clearance ≥50mL/min according to the Cockroft-Gault formula (or local institutional standard method)
Beta HCG level of 14 mIU/mL or below for women of childbearing potential
Highly effective contraception for patients if the risk of conception exists
Exclusion Criteria:
Patients with highly suspicious or positive metastases to the pelvic lymph nodes
* Patients eligible for radical local excision without involvement of other organs
Any psychiatric condition that would prohibit the understanding or rendering of informed consent
Prior radiotherapy to the pelvis or groin area limiting full dose chemoradiation according to protocol
Existing neuropathy which will hinder the intake of chemotherapy
Vulva carcinoma
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Frederic Amant, Prof. | Contact | 0031205129111 | f.amant@nki.nl |
| Name | Affiliation | Role |
|---|---|---|
| Frederic Amant, Prof. | NKI-AvL | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NKI-AVL | Recruiting | Amsterdam | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38719277 | Derived | Amant F, van Velzen AF, Reyners A, Zijlmans H, Schaake EE, Nooij L. Primary chemoradiation versus neoadjuvant chemotherapy followed by surgery as treatment strategy for locally advanced vulvar carcinoma (VULCANize2). Int J Gynecol Cancer. 2024 Oct 7;34(10):1639-1642. doi: 10.1136/ijgc-2024-005493. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Chemoradiation | Combination Product | According to standard treatment. |
|
| 24 months after completed treatment |
| Disease free survival | 24 months after completed treatment |
| Patterns of recurrence of disease | Type of recurrence after treatment: local, regional or distant recurrence | 24 months after completed treatment |
| Overall survival | 24 months after completed treatment |
| Treatment related death | 24 months after completed treatment |
| Prevention of trimodal treatment | Proportion of patients that don't need adjuvant surgery (arm 1) and number of patients that don't need adjuvant radiotherapy (arm 2) | 24 months after completed treatment |
| Functional organ preservation | Proportion of patients for who an organ-sparing surgery is possible | 24 months after completed treatment |
| Short term and long term complications | According to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 | 24 months after completed treatment |
| LUMC | Recruiting | Leiden | Netherlands |
|
| ID | Term |
|---|---|
| D017239 | Paclitaxel |
| D016190 | Carboplatin |
| D059248 | Chemoradiotherapy |
| ID | Term |
|---|---|
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D004224 | Diterpenes |
| D013729 | Terpenes |
| D056831 | Coordination Complexes |
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
| D004358 | Drug Therapy |
| D011878 | Radiotherapy |
Not provided
Not provided